Key result
Higher serum levels of LpA-I in the acute phase of STEMI independently predicted high on-treatment platelet reactivity (OR 1.03; 95% CI 1-1.07; p=0.049).
Why the study?
Are serum levels of LpA-I and LpA-I/A-II associated with high on-treatment platelet reactivity in patients with acute STEMI?
Observational (n=52)
Are serum levels of LpA-I and LpA-I/A-II associated with high on-treatment platelet reactivity in patients with acute STEMI?
Odds Ratio: 1.03 (95% CI 1–1.07)
p-value: p=0.049
Higher serum levels of LpA-I in the acute phase of STEMI are independently associated with high on-treatment platelet reactivity to clopidogrel.
LpA-I may mark clopidogrel nonresponse in acute STEMI; leaves open whether measurement should guide therapy.
OBJECTIVE: High-density lipoproteins (HDLs) are a very heterogeneous group of particles. Little is known about the impact of their subfractions including lipoprotein A-I (LpA-I) and lipoprotein A-I/A-II (LpA-I/A-II) on platelet function and high on-treatment platelet reactivity (HPR), particularly in the acute phase of ST-segment elevation myocardial infarction (STEMI). The aim of the study was to evaluate the relationship between serum levels of LpA-I and LpA-I/A-II and HPR in STEMI patients. METHODS: Fifty-two consecutive STEMI patients (26.9% women, mean age 60.6±9.1 years) were enrolled into this study. Clinical and demographic data were collected and HDL subfractions were measured by rocket immunoelectrophoresis. Platelet reactivity was assessed using light transmission aggregometry and quantitative flow cytometry. RESULTS: We found a positive correlation between platelet aggregation after both ADP-5 and ADP-20 stimulation and serum level of LpA-I. Compared with subjects with satisfactory platelet response to clopidogrel, patients with HPR had 32.44% higher serum level of LpA-I (p=0.021). On the other hand, patients with HPR assessed by ADP-5 stimulation had 22.13% lower serum level of LpA-I/A-II (p=0.040). Regression analysis showed that LpA-I [odds ratio (OR) 1.03; 95% confidence interval (CI) 1-1.07; p=0.049] and current smoking (OR 0.18; 95% CI 0.04-0.81; p=0.025) were independent predictors of HPR. With receiver operating characteristic (ROC) curve analysis, we designated the cut-off point at serum level of 57.52 mg/dL for LpA-I for predicting HPR (AUC=0.71, p=0.010). CONCLUSION: This study showed that higher serum level of LpA-I measured in the acute phase of STEMI is an independent risk factor for HPR. Our study is the first to demonstrate an important and distinct activity of LpA-I and LpA-I/A-II that can prove pleiotropic and different functions of HDL subfractions in acute STEMI.
No takes yet. Share an insight, caveat, or question.
Aleksander Siniarski (2018) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=52). Serum levels of lipoprotein A-I (LpA-I) vs. Lower serum levels was evaluated on High on-treatment platelet reactivity (HPR) (OR 1.03, 95% CI 1-1.07, p=0.049). Higher serum levels of LpA-I in the acute phase of STEMI independently predicted high on-treatment platelet reactivity (OR 1.03; 95% CI 1-1.07; p=0.049).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: